Acceleron gets FDA orphan drug designation for sotatercept in pulmonary arterial hypertension
“We’re pleased that the FDA has granted this designation for sotatercept,” said Janethe de Oliveira Pena, MD, PhD, Vice President, Pulmonary Medical Research at Acceleron. “In preclinical studies,